Recent Updates
Recently added Catalysts

Obicetrapib

Phase 3

Atherosclerotic Cardiovascular Disease | Small molecule | Cardiovascular |NewAmsterdam Pharma Company N.V.|Last Updated: Oct 19, 2025

Success Probability
Subscribe to view
Market & Valuation
Subscribe to view
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment9,541
FDA Designations
No designations recorded
Clinical trial landscape

Obicetrapib · 14 trials · 17 indications

Phase 3 3Phase 2 6Phase 1 5
NCT05425745Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies.Dyslipidemias
COMPLETED354 Analytics
NCT05202509Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular DiseaseAtherosclerotic Cardiovascular Disease
ACTIVE NOT_RECRUITING9,541 Analytics
NCT05142722Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying TherapiesDyslipidemias
COMPLETED2,530 Analytics
PHASE3COMPLETED
Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies.
Dyslipidemias
NCT05425745354
Unlock trial analytics
PHASE3ACTIVE NOT_RECRUITING
Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease
Atherosclerotic Cardiovascular Disease
NCT052025099,541
Unlock trial analytics
PHASE3COMPLETED
Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies
Dyslipidemias
NCT051427222,530
Unlock trial analytics
Study Design & Arms
Interventions
NameTypeDescription
ObicetrapibDRUG10 mg Obicetrapib tablet
PlaceboDRUGplacebo tablet made to resemble active
Obicetrapib 10mgDRUGActive Drug
Ezetimibe 10mgDRUGcapsules; 10 mg ezetimibe tablets filled into capsule shells, 1 tablet per capsule.
Obicetrapib placeboOTHERtablets; no active ingredient
Ezetimibe placeboOTHERcapsules; no active ingredient
Obicetrapib 5mgDRUGtablet
Obicetrapib + Drospirenone / Ethinyl Estradiol (COC)DRUGoral administration
Drospirenone / Ethinyl Estradiol (COC)DRUGoral administration
Atorvastatin CalciumDRUGAtorvastatin 80 mg
Rosuvastatin CalciumDRUGRosuvastatin 40 mg
Unlock Study Design Details
Recent Changes (Last 90 Days)
LOWMay 24, 2026NCT06982508studyFirstPostDate: changed
LOWMay 24, 2026NCT05972278studyFirstPostDate: changed
LOWMay 24, 2026NCT05202509studyFirstPostDate: changed